Form 4: Cero Therapeutics Holdings, Inc. Executive Acquires Stock Options

Daniel Corey, Chief Technical Officer of Cero Therapeutics Holdings, Inc., acquired stock options for 856,671 shares on March 25, 2024.

Summary

• Daniel Corey, the Chief Technical Officer of Cero Therapeutics Holdings, Inc., filed a Form 4 on March 27, 2024, reporting a transaction.
• On March 25, 2024, Corey acquired stock options for 856,671 shares of Cero Therapeutics common stock at an exercise price of $1.77 per share.
• 395,387 of these shares are immediately vested and exercisable.
• The remaining shares will vest in 48 monthly installments following the grant date, contingent upon Corey's continued service.

Sentiment

Score: 6

Explanation: Neutral sentiment. This is a routine disclosure of stock option grants to an executive. It doesn't inherently indicate positive or negative performance, but rather provides transparency into executive compensation.

Positives

• The acquisition of stock options by a key executive could signal confidence in the company's future prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track executive compensation and potential alignment of interests.

Stakeholder Impact

• Shareholders may view this as a positive sign if they believe it aligns the executive's interests with the company's long-term success.

Key Dates

Keywords

Stock Options, Form 4, Cero Therapeutics Holdings, Daniel Corey, Chief Technical Officer, Beneficial Ownership